

**AMENDMENTS TO THE CLAIMS**

**Claim 1. (currently amended) A method of treating uterine serous papillary carcinoma that over-express HER-2/neu, comprising the step of administering to an individual with said carcinoma a therapeutically effective dose of humanized murine anti-HER-2/neu monoclonal antibody 4D5 (HERCEPTIN®) that binds to the p185 extracellular domain of HER-2/neu.**

**Claim 2 (canceled).**

**Claim 3-4 (canceled)**

**Claim 5 (previously amended) The method of claim 1, wherein said antibody is administered to said individual in a dose of from about 4 mg/kg to about 8 mg/kg.**

**Claims 6-18 (canceled)**